Clinical trials: Anti-PD-1
Glioblastoma
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).
- Trial name
- NCT04225039
- Testing
- INCMGA00012, INCAGN01876, SRS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Stage IIIA Hepatocellular Carcinoma
Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma
The purpose of this clinical research study is to investigate the efficacy and safety of Radiotherapy Combined with TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma with Portal Vein Tumor Thrombus(PVTT).
- Trial name
- NCT06061445
- Testing
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fujian Cancer Hospital
Immune Checkpoint Inhibitors, Lung Cancer
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognosis(secondary) in the…
- Trial name
- NCT05288569
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
This is a phase II, open-labeled, multi-centered,single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with apatinib (a VEGFR2 TKI) and eribulin mesylate in patients with…
- Trial name
- NCT04303741
- Testing
- Camrelizumab, Apatinib, Eribulin
- Where
- 3 sites in China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hodgkin Lymphoma
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma.
- Trial name
- NCT04026269
- Testing
- MOAP
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Han weidong
Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- 2018/00947 (NCT03813394)
- Testing
- pembrolizumab, bevacizumab
- Where
- Singapore
- Volunteers
- 48 people
- Sponsor
- National University Hospital, Singapore
Non-Small Cell Lung Cancer, Chemotherapy
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics…
- Conditions
- Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
- Trial name
- NCT06896422
- Testing
- Glutathione, PD1 Inhibitor, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Head and Neck Squamous Cell Carcinoma
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on pain, anxiety and depression in patients with operable head and neck squamous…
- Trial name
- NCT06575322
- Testing
- Carboplatin（ neoadjuvant）, Paclitaxel （neoadjuvant）, Anti-PD-1 Drugs
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Astrocytoma of Brain
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma
This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years)…
- Trial name
- NCT05518994
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Provincial People's Hospital
Clear Cell Renal Cell Carcinoma
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
This study will evaluate the use of nivolumab before surgery in patients with high-risk clear cell renal cell carcinoma who are eligible for nephrectomy.
- Trial name
- NCT02575222
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Urothelial Cancer
RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
This is a pilot study of a fixed dose of Pembrolizumab in combination with two different regimens of hypofractionated radiation.
- Trial name
- NCT02880345
- Testing
- PEMBROLIZUMAB, hypofractionated radiation
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Melanoma
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
This study evaluates nivolumab in combination drug treatments involving 1) nivolumab and dabrafenib 2) nivolumab and trametinib and 3) nivolumab, dabrafenib and trametinib in patients with BRAF or NRAS-mutated metastatic melanoma.
- Trial name
- NCT02357732
- Testing
- Nivolumab, Trametinib, Dabrafenib
- Sponsor
- University of Pittsburgh
Liver Cancer, Lung Cancer
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion…
- Conditions
- Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
- Trial name
- NCT04842812
- Testing
- TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Pleural Mesotheliomas
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Multicentre, open-label, single arm phase II study for patients with PM previously treated by immunotherapy and standard chemotherapy.
- Trial name
- Bi-MAPS (NCT06840834)
- Testing
- Ivonescimab
- Where
- 21 sites in France
- Volunteers
- 38 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Melanoma
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene…
- Trial name
- NCT05983237
- Testing
- Fluzoparib Camrelizumab Temozolomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jun Guo
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03642067
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor
EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT
This study is for people who have high-risk Ewing sarcoma (ES), or a related Ewing's family tumor, desmoplastic small round cell tumor (DSRCT).
- Trial name
- NCT07695311
- Testing
- EWSR1 immunotherapy, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Rabi Hanna
Advanced/Metastatic Solid Tumors
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors.
- Trial name
- NCT05277402
- Testing
- ADG116
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adagene Inc
Cancer
PULSAR Radiotherapy Plus Anti-PD-1 Therapy in Metastatic Abdominopelvic Tumors
This study evaluates hypofractionated radiotherapy combined with PD-1 inhibitor-based systemic therapy in patients with metastatic solid tumors.
- Trial name
- NCT07383857
- Testing
- pulsed radiotherapy
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Zhen Zhang
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.